{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:54:21Z","timestamp":1790924061615,"version":"4.1.0"},"reference-count":121,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"DOI":"10.1080\/14728214.2026.2739626","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:36:18Z","timestamp":1790865378000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Emerging drugs for diabetic macular edema: an update"],"prefix":"10.1080","author":[{"given":"Charles","family":"Zhang","sequence":"first","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]},{"name":"Retinal Consultants of Texas","place":["Bellaire, USA"]},{"name":"The State University of New York at Buffalo","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Ersan","sequence":"additional","affiliation":[{"name":"The State University of New York at Buffalo","place":["Buffalo, USA"]},{"name":"Medical University of South Carolina","place":["Charleston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Virk","sequence":"additional","affiliation":[{"name":"University of Arizona","place":["Phoenix, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Higgins","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid U.","family":"Scott","sequence":"additional","affiliation":[{"name":"Penn State College of Medicine","place":["Hershey, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Harry W.","family":"Flynn","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S001"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2289"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909637"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001555"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412013312203"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30052-3"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14891"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0317"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01377-x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6386"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.06.014"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100940"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00154"},{"issue":"3","key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13543784.2020.1723078","article-title":"Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment","volume":"29","author":"Bhatwadekar AD","year":"2020","unstructured":"Bhatwadekar AD, Kansara VS, Ciulla TA. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. Expert Opin Investig Drugs. 2020;29(3):237\u2013244.","journal-title":"Expert Opin Investig Drugs"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.006"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.032"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.05.017"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101219"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2025.08.017"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x"},{"issue":"4","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","article-title":"Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial","volume":"143","author":"Khanani AM","year":"2025","unstructured":"Khanani AM, Campochiaro PA, Graff JM, et al. Continuous ranibizumab via port delivery system vs monthly ranibizumab for treatment of diabetic macular edema: the pagoda randomized clinical trial. JAMA Ophthalmol. 2025;143(4):326\u2013335.","journal-title":"JAMA Ophthalmol"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.024"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.12.018"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.6565"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0606-9"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.1963"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0522-z"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.06.030"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub7"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.4914"},{"key":"e_1_3_4_36_1","first-page":"bjo-2025","article-title":"Outcomes of eyes with persistent diabetic macular oedema: the Fight Retinal Blindness!","author":"Fraser-Bell S","year":"2026","unstructured":"Fraser-Bell S, Lee N-Y, Hashimoto Y, et al. Outcomes of eyes with persistent diabetic macular oedema: the Fight Retinal Blindness! Project Br J Ophthalmol. 2026:bjo-2025\u2013328621.","journal-title":"Project Br J Ophthalmol"},{"issue":"8","key":"e_1_3_4_37_1","first-page":"3791","article-title":"Visual outcomes after early dexamethasone implant in patients with diabetic macular edema compared to standard of Care: ERLYDEX study","volume":"66","author":"Skondra D","year":"2025","unstructured":"Skondra D, Sadda SR, Wykoff CC, et al. Visual outcomes after early dexamethasone implant in patients with diabetic macular edema compared to standard of Care: ERLYDEX study. Invest Ophthalmol Vis Sci. 2025;66(8):3791.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1761325"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2024-326006"},{"key":"e_1_3_4_40_1","unstructured":"A Phase iii multicenter randomized double-blind Active controlled trial of RC28-E intravitreal injection in subjects with diabetic macular edema. 2023."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.107823"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00350-X"},{"key":"e_1_3_4_43_1","unstructured":"ClinicalTrials.gov. A multicenter non-randomized open-label multiple-dose-escalation and dose-expansion study to evaluate the safety tolerability pharmacokinetics and efficacy of ASKG712 following intravitreal administration in patients with diabetic macular edema. NCT05940428. 2023."},{"issue":"8","key":"e_1_3_4_44_1","first-page":"2377","article-title":"Phase 1 study of ASKG712 (anti-VEGF-A\/Ang-2 bispecific antibody) for diabetic macular edema (DME)","volume":"66","author":"Zhang W","year":"2025","unstructured":"Zhang W, Chen Y, Lu P, et al. Phase 1 study of ASKG712 (anti-VEGF-A\/Ang-2 bispecific antibody) for diabetic macular edema (DME). Invest Ophthalmol Vis Sci. 2025;66(8):2377.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"e_1_3_4_47_1","unstructured":"A Phase 1\/2a 2-part study consisting of an open-label multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO) and a dose-finding double-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE201 (tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (NVAMD). 2024."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100966"},{"key":"e_1_3_4_49_1","unstructured":"ClinicalTrial.gov. A multicenter open-labeled Phase 2a study evaluating the safety tolerability and efficacy of intravitreal AG-73305 in patients with diabetic macular edema. NCT05301751. 2022."},{"key":"e_1_3_4_50_1","unstructured":"ClinicalTrials.gov. A Phase ii multicenter randomized double masked Active comparator-controlled study to investigate the efficacy safety tolerability pharmacokinetics and pharmacodynamics of RO7200220 administered Intravitreally in patients with diabetic macular edema. NCT05151731. 2021."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2026.0610"},{"key":"e_1_3_4_52_1","unstructured":"ClinicalTrials.gov. A Phase ii multicenter randomized double masked Active comparator-controlled study to investigate the efficacy safety tolerability pharmacokinetics and pharmacodynamics of RO7200220 in combination with ranibizumab administered intravitreally in patients with diabetic macular edema. NCT05151744. 2021."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2177"},{"key":"e_1_3_4_54_1","unstructured":"ClinicalTrials.gov. A randomized double-maskedblind activity-controlled Phase ii clinical study to evaluateing the efficacy and safety of intravitreal injection of IBI302 in patients with diabetic macular edema (DME) subjects.NCT06908876. 2025."},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.12.011"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0335390"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.25029"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.2809"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.011273"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba7457"},{"key":"e_1_3_4_63_1","unstructured":"ClinicalTrials.gov. A randomized double-masked multi-center 3-arm pivotal Phase 2\/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5mg) in participants with diabetic macular edema. NCT06571045. 2024."},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.11.008"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243497"},{"key":"e_1_3_4_66_1","unstructured":"A randomized open-label parallel-group multi-center Phase 2a study to evaluate the efficacy and safety of CU06-1004 for 12\u00a0weeks in patients with diabetic macular edema (DME). 2022."},{"key":"e_1_3_4_67_1","unstructured":"Gonzalez V. Phase 2a study of CU06-1004 an Oral endothelial dysfunction blocker for the treatment of diabetic macular edema (DME). 2024."},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02802-4"},{"issue":"4","key":"e_1_3_4_69_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2021.01.011","article-title":"Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition","volume":"33","author":"Crespo-Garcia S","year":"2021","unstructured":"Crespo-Garcia S, Tsuruda PR, Dejda A, et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 2021;33(4):818\u2013832.e7.","journal-title":"Cell Metab"},{"key":"e_1_3_4_70_1","unstructured":"ClinicalTrials.gov. A Phase 2a prospective multicenter randomized double masked sham-controlled study to assess the safety tolerability and evidence of activity of a single intravitreal injection of UBX1325 in patients with diabetic macular edema. NCT04857996. 2021."},{"key":"e_1_3_4_71_1","unstructured":"ClinicalTrials.gov. A Phase 2b prospective multicenter randomized double-masked Active-controlled study to assess the efficacy and safety of repeat intravitreal injections of foselutoclax (UBX1325) in patients with diabetic macular edema. NCT06011798. 2023."},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400009"},{"issue":"8","key":"e_1_3_4_73_1","first-page":"4014","article-title":"Safety and efficacy of senolytic candidate UBX1325 for diabetic macular edema: the behold Phase 2 and aspire Phase 2b trials","volume":"66","author":"Khanani AM","year":"2025","unstructured":"Khanani AM, Klier S, Masaki L, et al. Safety and efficacy of senolytic candidate UBX1325 for diabetic macular edema: the behold Phase 2 and aspire Phase 2b trials. Invest Ophthalmol Vis Sci. 2025;66(8):4014.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.06.001"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-016-1002-6"},{"key":"e_1_3_4_76_1","unstructured":"ClinicalTrials.gov. A randomized double-masked placebo-controlled parallel-arm study to evaluate the efficacy and safety of RZ402 in participants with diabetic macular edema (DME). NCT05712720. 2023."},{"key":"e_1_3_4_77_1","unstructured":"Rezolute Inc. Rezolute reports positive topline results from Phase 2 proof-of-concept study of RZ402 in patients with diabetic macular edema (DME). GlobeNewswire; 2024."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101167"},{"key":"e_1_3_4_79_1","unstructured":"A Phase 2 Evaluation of Tonabersat for diabetic macular edema (protocol an). 2023."},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.6035"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.06.010"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/20415990.2024.2406226"},{"key":"e_1_3_4_83_1","unstructured":"EyePoint Pharmaceuticals Inc. A Phase 3 multicenter prospective randomized double-masked parallel-group study of EYP-1901 a tyrosine kinase inhibitor (TKI) compared to aflibercept (2 mg) in participants with diabetic macular edema (DME). [Internet]. clinicaltrials.gov; 2026 [cited 2026 Jul 20]. Report No.: NCT07449923. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07449923"},{"key":"e_1_3_4_84_1","unstructured":"ClinicalTrials.gov. A Phase 2 multicenter randomized double-masked parallel-group study to assess the efficacy and safety of KHK4951 a vascular endothelial growth factor receptor inhibitor in patients with diabetic macular edema. NCT06116916. 2023."},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2334"},{"key":"e_1_3_4_86_1","unstructured":"ClinicalTrials.gov. A study to evaluate the safety tolerability and pharmacokinetics of D-4517.2 after subcutaneous administration in subjects with neovascular (wet) age-related macular degeneration (AMD) or subjects with diabetic macular edema (DME). NCT05387837. 2022."},{"key":"e_1_3_4_87_1","unstructured":"Retinal Physician. Migaldendranib demonstrates efficacy in DME and nAMD. Retinal Physician. 2025 Sep 5. Available from: https:\/\/retinalphysician.com\/issues\/2025\/september\/euretina6\/"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011599.pub2"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051327"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_68_19"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.11.003"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14861"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15215"},{"key":"e_1_3_4_94_1","unstructured":"A Phase 3 double-masked randomized multicenter study of the efficacy and safety of OCS 01 Eye drops in subjects with diabetic macular edema. 2023."},{"key":"e_1_3_4_95_1","unstructured":"Multi-Center A Randomized P-G. Phase 2 masked three-arm trial to compare safety tolerability efficacy and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone Microspheres; DEXAspheres\u00ae) using the Oxulumis\u00ae illuminated microcatheterization device compared with intravitreal dexamethasone implant (OZURDEX\u00ae) in subjects with diabetic macular edema (oxeye). 2023."},{"issue":"2","key":"e_1_3_4_96_1","first-page":"S19","article-title":"Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety","volume":"29","author":"Yeh S","year":"2023","unstructured":"Yeh S, Ciulla T. Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with noninfectious uveitis: an in-depth look at efficacy and safety. Am J Manag Care. 2023;29(2 Suppl):S19\u2013s28.","journal-title":"Am J Manag Care"},{"issue":"5","key":"e_1_3_4_97_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jama.2025.4358","article-title":"Uveitis in adults: a review","volume":"334","author":"Maghsoudlou P","year":"2025","unstructured":"Maghsoudlou P, Epps SJ, Guly CM, et al. Uveitis in adults: a review. JAMA. 2025;334(5):419\u2013434.","journal-title":"JAMA"},{"key":"e_1_3_4_98_1","unstructured":"Randomized A. Controlled subject- and evaluator-masked Phase 2 clinical trial comparing EC-104 intravitreal implant to Ozurdex\u00ae for the treatment of diabetic macular edema (BETTIS-1). 2024."},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093205"},{"issue":"4","key":"e_1_3_4_100_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow JJL","year":"2019","unstructured":"Darrow JJL. FDA documents reveal the value of a costly gene therapy. Drug Discov Today. 2019;24(4):949\u2013954.","journal-title":"Drug Discov Today"},{"key":"e_1_3_4_101_1","unstructured":"A Phase 2 multi-center randomized double-masked Active controlled study of ADVM-022 (AAV.7m8-aflibercept) in subjects with diabetic macular edema [infinity]. 2020."},{"key":"e_1_3_4_102_1","volume-title":"Clinical data on ADVM-022 in diabetic macular edema (infinity trial)","author":"Adverum Biotechnologies","year":"2021","unstructured":"Adverum Biotechnologies. Clinical data on ADVM-022 in diabetic macular edema (infinity trial). 2021."},{"key":"e_1_3_4_103_1","unstructured":"Adverum Biotechnologies. Clinical data from the optic trial of ADVM-022 in wet age-related macular degeneration. 2021."},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.14.1"},{"key":"e_1_3_4_105_1","unstructured":"A Phase 2 randomized Active-controlled double-masked trial of intravitreal 4D-150 gene therapy in adults with diabetic macular edema (spectra). 2023."},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00310-6"},{"key":"e_1_3_4_107_1","unstructured":"A Phase 2 randomized controlled dose-escalation study to evaluate the efficacy safety and tolerability of RGX-314 gene therapy delivered via a single suprachoroidal space (SCS) injections in participants with diabetic retinopathy (DR) with and without center involved-diabetic macular edema (CI-DME)(ALTITUDE). 2020."},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2019.0126"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S364200"},{"key":"e_1_3_4_110_1","unstructured":"A dose-escalation and dose-expanded Phase I\/II clinical study to evaluate the safety and efficacy of FT-003 in subjects with DME. 2024."},{"issue":"8","key":"e_1_3_4_111_1","first-page":"4013","article-title":"Interim results for Phase I study of intravitreal gene therapy FT-003 in patients with diabetic macular edema (DME)","volume":"66","author":"Li X","year":"2025","unstructured":"Li X, Li X, Xing D, et al. Interim results for Phase I study of intravitreal gene therapy FT-003 in patients with diabetic macular edema (DME). Invest Ophthalmol Vis Sci. 2025;66(8):4013.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016315"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004167"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23042"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64332-6"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.0606"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.5248"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.1819"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.12.020"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2025-328196"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.1669"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S100168"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2739626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14728214.2026.2739626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2026.2739626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:26:37Z","timestamp":1790922397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2026.2739626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":121,"alternative-id":["10.1080\/14728214.2026.2739626"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2026.2739626","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}